GLUE实时信号 | 通过Getagraph.com最大化利润

出售 119624 min ago

@ $4.87

发出时间: 9 Feb 2024 @ 23:05

回报率: 13.40%

上一信号: Feb 8 - 03:34

上一信号: 购买

回报率: 3.99 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 00:47):

Stats
今日成交量	26 558.00
平均成交量	137 065
市值	277.10M
EPS	$0 ( 2024-03-21 )
下一个收益日期	( $-0.560 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.10
ATR14	$0.0340 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Warmuth Markus	Buy	346 000	Stock Option (Right to Buy)
2024-01-02	Wallace Owen B.	Buy	119 000	Stock Option (Right to Buy)
2024-01-02	Jones Jullian G	Buy	79 000	Stock Option (Right to Buy)
2024-01-02	Janku Filip	Buy	121 000	Stock Option (Right to Buy)
2024-01-02	Nickson Philip	Buy	109 000	Stock Option (Right to Buy)

INSIDER POWER
92.64
Last 98 transactions
Buy: 57 206 836 \| Sell: 164 598 288

音量相关性

長: 0.31 (neutral)

短: -0.77 (moderate negative)

Signal:(41.563) Neutral

Monte Rosa Therapeutics, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Monte Rosa Therapeutics, 相关性 - 货币/商品

0.58
( weak )

0.61
( weak )

0.00
( neutral )

0.60
( weak )

-0.81
( strong negative )

0.72
( moderate )

Monte Rosa Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-6.22M (0.00 %)
EPS:	$-2.63

FY	2023
营收:	$0
毛利润:	$-6.22M (0.00 %)
EPS:	$-2.63

FY	2022
营收:	$0
毛利润:	$-8.56M (0.00 %)
EPS:	$-2.22

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-6.64

Financial Reports:

No articles found.

Monte Rosa Therapeutics,

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.